Karen L Marquis

Summary

Affiliation: Wyeth Research
Country: USA

Publications

  1. ncbi request reprint WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity
    Karen L Marquis
    Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, NJ 08543, USA
    J Pharmacol Exp Ther 320:486-96. 2007
  2. doi request reprint WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity
    Julie A Brennan
    Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA
    J Pharmacol Exp Ther 332:190-201. 2010
  3. doi request reprint Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia
    Steven M Grauer
    Wyeth Discovery Neuroscience, Wyeth Research, CN8000, Princeton, New Jersey 08543, USA
    J Pharmacol Exp Ther 331:574-90. 2009
  4. doi request reprint The orphan GPCR, GPR88, modulates function of the striatal dopamine system: a possible therapeutic target for psychiatric disorders?
    Sheree F Logue
    Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, NJ 08543, USA
    Mol Cell Neurosci 42:438-47. 2009
  5. doi request reprint WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics
    Steven M Grauer
    Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, NJ 08543, USA
    Psychopharmacology (Berl) 204:37-48. 2009
  6. doi request reprint ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities
    Feng Liu
    Wyeth Neuroscience Discovery Research, Princeton, New Jersey, USA
    J Pharmacol Exp Ther 327:827-39. 2008
  7. doi request reprint Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist
    Robert H Ring
    Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA
    Neuropharmacology 58:69-77. 2010
  8. doi request reprint Potent dihydroquinolinone dopamine D2 partial agonist/serotonin reuptake inhibitors for the treatment of schizophrenia
    Yinfa Yan
    Chemical Sciences, Wyeth Research, CN 8000 Princeton, NJ 08543, United States
    Bioorg Med Chem Lett 20:2983-6. 2010
  9. ncbi request reprint Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents
    Sharon Rosenzweig-Lipson
    Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, NJ 08543, USA
    Psychopharmacology (Berl) 192:159-70. 2007
  10. doi request reprint Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists
    Julia N Heinrich
    Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, NJ 08543, USA
    Eur J Pharmacol 605:53-6. 2009

Detail Information

Publications16

  1. ncbi request reprint WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity
    Karen L Marquis
    Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, NJ 08543, USA
    J Pharmacol Exp Ther 320:486-96. 2007
    ..p.). Thus, the profile of the 5-HT2C selective receptor agonist WAY-163909 is similar to that of an atypical antipsychotic and additionally may have rapid onset properties...
  2. doi request reprint WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity
    Julie A Brennan
    Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA
    J Pharmacol Exp Ther 332:190-201. 2010
    ..Furthermore, WS-50030 provides a tool to further explore how combining these mechanisms might differentiate from other antipsychotics or antidepressants...
  3. doi request reprint Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia
    Steven M Grauer
    Wyeth Discovery Neuroscience, Wyeth Research, CN8000, Princeton, New Jersey 08543, USA
    J Pharmacol Exp Ther 331:574-90. 2009
    ..Together, our results suggest that PDE10A inhibitors alleviate both dopaminergic and glutamatergic dysfunction thought to underlie schizophrenia, which may contribute to the broad-spectrum efficacy...
  4. doi request reprint The orphan GPCR, GPR88, modulates function of the striatal dopamine system: a possible therapeutic target for psychiatric disorders?
    Sheree F Logue
    Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, NJ 08543, USA
    Mol Cell Neurosci 42:438-47. 2009
    ..Antipsychotic administration to Gpr88KOs normalized the PPI deficit and blocked AICS. The modulatory role of Gpr88 in striatal dopamine function suggests it may be a new target for treatments for psychiatric disorders...
  5. doi request reprint WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics
    Steven M Grauer
    Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, NJ 08543, USA
    Psychopharmacology (Berl) 204:37-48. 2009
    ....
  6. doi request reprint ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities
    Feng Liu
    Wyeth Neuroscience Discovery Research, Princeton, New Jersey, USA
    J Pharmacol Exp Ther 327:827-39. 2008
    ..p.) in rats. Taken together, these effects are consistent with the hypothesis that allosteric potentiation of mGlu5 may provide a novel approach for development of antipsychotic and procognitive agents...
  7. doi request reprint Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist
    Robert H Ring
    Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA
    Neuropharmacology 58:69-77. 2010
    ..A selective OTR antagonist also failed to block the effects of OT on immobility in the TST. The significance of these findings for shaping the clinical development of OTR agonists is discussed...
  8. doi request reprint Potent dihydroquinolinone dopamine D2 partial agonist/serotonin reuptake inhibitors for the treatment of schizophrenia
    Yinfa Yan
    Chemical Sciences, Wyeth Research, CN 8000 Princeton, NJ 08543, United States
    Bioorg Med Chem Lett 20:2983-6. 2010
    ..Structure-activity studies revealed that the linker plays a key role in contributing to D(2) affinity, function, and SRI activity...
  9. ncbi request reprint Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents
    Sharon Rosenzweig-Lipson
    Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, NJ 08543, USA
    Psychopharmacology (Berl) 192:159-70. 2007
    ..Activation of one or more of the serotonin (5-HT) receptors may play a role in mediating the antidepressant effects of SSRIs...
  10. doi request reprint Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists
    Julia N Heinrich
    Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, NJ 08543, USA
    Eur J Pharmacol 605:53-6. 2009
    ....
  11. ncbi request reprint Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease
    Thomas A Comery
    Discovery Neuroscience, Wyeth Research, CN8000, Princeton, New Jersey 08543, USA
    J Neurosci 25:8898-902. 2005
    ..Furthermore, they suggest that acute treatment with GSI may provide improved cognitive functioning as well as disease-modifying effects in Alzheimer's disease...
  12. ncbi request reprint Pharmacological profile of the 5-HT(2C) receptor agonist WAY-163909; therapeutic potential in multiple indications
    John Dunlop
    Discovery Neuroscience, Wyeth Research, Princeton, NJ 08543, USA
    CNS Drug Rev 12:167-77. 2006
    ..Consistent with a potential therapeutic utility in obesity, schizophrenia and depression WAY-163909 was found to have robust dose-dependent effects in animal models of obesity, psychotic-like behavior or depression...
  13. doi request reprint 5-HT2C receptor agonists as an innovative approach for psychiatric disorders
    Sharon Rosenzweig-Lipson
    Wyeth Discovery Neuroscience, Princeton, New Jersey 08543, USA
    Drug News Perspect 20:565-71. 2007
    ..The current review highlights the underlying complexities of this area and provides the rationale for using 5-HT(2C) agonists in the treatment of both schizophrenia and depressive disorders...
  14. doi request reprint Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia
    David P Rotella
    Chemical Sciences, Wyeth Research, CN 8000 Princeton, NJ 08543, United States
    Bioorg Med Chem Lett 19:5552-5. 2009
    ..This approach has the potential to treat a broader range of symptoms compared to existing therapies. Selected compounds in this series demonstrate high affinity for both targets and D2 partial agonism in cell-based and in vivo assays...
  15. ncbi request reprint Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist
    Julia N Heinrich
    Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543 8000, USA
    Eur J Pharmacol 552:36-45. 2006
    ..The dopamine D(2) receptor selective partial agonist profile of aplindore suggests that it should be effective for the treatment of dopaminergic-based disorders, such as schizophrenia and Parkinson's disease...
  16. doi request reprint Activation of estrogen receptor-beta regulates hippocampal synaptic plasticity and improves memory
    Feng Liu
    Wyeth Research, Discovery Neuroscience, 865 Ridge Road, Monmouth Junction, New Jersey 08852, USA
    Nat Neurosci 11:334-43. 2008
    ..Our data suggest that activation of ERbeta can regulate hippocampal synaptic plasticity and improve hippocampus-dependent cognition...